PremiumThe FlyBarinthus CSO Nadege Pelletier to depart, Geoffrey Lynn to succeed Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results Barinthus announces results from ongoing Phase 2b HBV003 trial PremiumThe FlyBarinthus Bio completes enrollment for hepatitis B, prostate cancer trials Barinthus Biotherapeutics initiates Phase 1 clinical trial of VTP-1000 Barinthus Biotherapeutics Elevates Griffiths to COO PremiumThe FlyBarinthus Biotherapeutics to prioritize VTP-300, reduce workforce by 25% Barinthus Biotherapeutics Breakthrough in Hepatitis B Treatment Barinthus presents EOT data from Phase 2a trial of imdusiran, VTP-300